ADVANTAGES OF BIOCHEMICAL METHODS OF DIAGNOSING FIBROSIS IN NON-ALCOHOLIC FATTY LIVER DISEASE IN ADOLESCENTS WITH OBESITY
Non-alcoholic fatty liver disease occurs in most obese people, the main pathway of which is the process of fibrogenesis. This disorder is currently classified into two types: hepatic steatosis and nonalcoholic steatohepatitis. Hepatic steatosis is a reversible condition in which large vacuoles of triglyceride fat accumulate in the liver cells, causing nonspecific inflammation. Most people with this condition experience few, if any, symptoms, and it does not usually lead to scarring or serious liver damage. The majority of patients with nonalcoholic fatty liver disease have this type. Nonalcoholic steatohepatitis is the more severe, progressive form that involves not only fat accumulation (steatosis) in the liver but also inflammation. Steatohepatitis can lead to fibrosis and eventually to cirrhosis, which is severe scarring that can lead to liver failure.
The real frequency of the prevalence of the disease is difficult to establish, due to the insufficient use of non-invasive screening diagnostic methods, through which it is possible to detect the initial forms of the disease.
The aim: to study the diagnostic significance of the serum biomarkers of liver fibrogenesis in adolescents with obesity.
Methods. On the base of the Department of Endocrinology, SI “Institute of children and adolescence health care of NAMS” (Kharkov) 226 patients with obesity aged 8–18 years were examined. Investigation of liver fibrosis consisted of measurement in blood the levels of fibronectin, collagen type IV, N-terminal propeptides and C-terminal telopeptides of type I collagen by IFA method.
Results. The study of liver fibrogenesis revealed a significant increase in levels of type IV collagen and fibronectin in children with obesity (p<0.05). As diagnostic criteria for two physiologically diverse processes – fibrogenesis and fibrolysis, the levels of N-terminal propeptides and C-terminal telopeptides of type I collagen, respectively, were determined. The serum level of N-terminal propeptides of type I collagen significantly exceeds the normal values in all children with obesity, in contrast to the children of the control group (p<0.05).
Conclusion. It has been established that a biochemical method for determining the level of type IV collagen, fibronectin, N-terminal propeptides and C-terminal telopeptides of type I collagen has a high sensitivity for the diagnosis of liver fibrogenesis.
Chalasani, N., Younossi, Z., Lavine, J. E., Diehl, A. M., Brunt, E. M., Cusi, K. et. al. (2012). The Diagnosis and Management of Non-alcoholic Fatty Liver Disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology and the American Gastroenterological Association. The American Journal of Gastroenterology, 107 (6), 811–826. doi: http://doi.org/10.1038/ajg.2012.128
Musso, G., Gambino, R., Cassader, M., Pagano, G. (2010). Meta-analysis: Natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity. Annals of Medicine, 43 (8), 617–649. doi: http://doi.org/10.3109/07853890.2010.518623
Bloomgarden, Z. T. (2005). Second World Congress on the Insulin Resistance Syndrome: Insulin resistance syndrome and nonalcoholic fatty liver disease. Diabetes Care, 28 (6), 1518–1523. doi: http://doi.org/10.2337/diacare.28.6.1518
Al-Hamad, D., Raman, V. (2017). Metabolic syndrome in children and adolescents. Translational Pediatrics, 6 (4), 397–407. doi: http://doi.org/10.21037/tp.2017.10.02
O’Neill, S., O’Driscoll, L. (2014). Metabolic syndrome: a closer look at the growing epidemic and its associated pathologies. Obesity Reviews, 16 (1), 1–12. doi: http://doi.org/10.1111/obr.12229
Polyzos, S. A., Mantzoros, C. S. (2016). Nonalcoholic fatty future disease. Metabolism, 65 (8), 1007–1016. doi: http://doi.org/10.1016/j.metabol.2015.12.009
Mantovani, A., Zaza, G., Byrne, C. D., Lonardo, A., Zoppini, G., Bonora, E., Targher, G. (2018). Nonalcoholic fatty liver disease increases risk of incident chronic kidney disease: A systematic review and meta-analysis. Metabolism, 79, 64–76. doi: http://doi.org/10.1016/j.metabol.2017.11.003
Della Corte, C., Alisi, A., Saccari, A., De Vito, R., Vania, A., Nobili, V. (2012). Nonalcoholic Fatty Liver in Children and Adolescents: An Overview. Journal of Adolescent Health, 51 (4), 305–312. doi: http://doi.org/10.1016/j.jadohealth.2012.01.010
McPherson, S., Stewart, S. F., Henderson, E., Burt, A. D., Day, C. P. (2010). Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease. Gut, 59 (9), 1265–1269. doi: http://doi.org/10.1136/gut.2010.216077
Alkhouri, N., Feldstein, A. E. (2016). Noninvasive diagnosis of nonalcoholic fatty liver disease: Are we there yet? Metabolism, 65 (8), 1087–1095. doi: http://doi.org/10.1016/j.metabol.2016.01.013
Jayakumar, S., Harrison, S. A., Loomba, R. (2016). Noninvasive Markers of Fibrosis and Inflammation in Nonalcoholic Fatty Liver Disease. Current Hepatology Reports, 15 (2), 86–95. doi: http://doi.org/10.1007/s11901-016-0296-8
Papagianni, M. (2015). Non-invasive methods for the diagnosis of nonalcoholic fatty liver disease. World Journal of Hepatology, 7 (4), 638–648. doi: http://doi.org/10.4254/wjh.v7.i4.638
Sanai, F., Keeffe, E. (2010). Liver biopsy for histological assessment – the case against. Saudi Journal of Gastroenterology, 16 (2), 124–132. doi: http://doi.org/10.4103/1319-3767.61244
Shah, A. G., Lydecker, A., Murray, K., Tetri, B. N., Contos, M. J., Sanyal, A. J. (2009). Comparison of Noninvasive Markers of Fibrosis in Patients With Nonalcoholic Fatty Liver Disease. Clinical Gastroenterology and Hepatology, 7 (10), 1104–1112. doi: http://doi.org/10.1016/j.cgh.2009.05.033
Cholongitas, E., Senzolo, M., Standish, R., Marelli, L., Quaglia, A., Patch, D. et. al. (2006). A Systematic Review of the Quality of Liver Biopsy Specimens. American Journal of Clinical Pathology, 125 (5), 710–721. doi: http://doi.org/10.1309/w3xcnt4hkfbn2g0b
Younossi, Z. M., Loomba, R., Anstee, Q. M., Rinella, M. E., Bugianesi, E., Marchesini, G. et. al. (2018). Diagnostic modalities for nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and associated fibrosis. Hepatology, 68 (1), 349–360. doi: http://doi.org/10.1002/hep.29721
👁 362 ⬇ 213
Copyright (c) 2018 Olena Buznytska
This work is licensed under a Creative Commons Attribution 4.0 International License.
Our journal abides by the Creative Commons CC BY copyright rights and permissions for open access journals.
Authors, who are published in this journal, agree to the following conditions:
1. The authors reserve the right to authorship of the work and pass the first publication right of this work to the journal under the terms of a Creative Commons CC BY, which allows others to freely distribute the published research with the obligatory reference to the authors of the original work and the first publication of the work in this journal.
2. The authors have the right to conclude separate supplement agreements that relate to non-exclusive work distribution in the form in which it has been published by the journal (for example, to upload the work to the online storage of the journal or publish it as part of a monograph), provided that the reference to the first publication of the work in this journal is included.